ClinicalTrials.gg
WithdrawnNCT01941004Updated Apr 21, 2017

Safety and Efficacy of Fingolimod in MS Patients in China

A Phase 3 interventional study of fingolimod and Placebo (6mos) + open label fingolimod (6 mos) in Multiple Sclerosis (Relapsing Remitting), sponsored by Novartis Pharmaceuticals. Withdrawn. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2017-04-21.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, 1 under way, none of them phase 3. fingolimod · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
19th of 19
0 · median 142
Started
2014
with 1 other
Phase 3
5 of 19
none open now
Registered
14th of 19
by date
Lead sponsor
14 of 19
Novartis Pharmaceuticals

Among the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting, this one is the 19th largest by enrollment, is one of 2 that started in 2014, is one of 5 in phase 3, and was the 14th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing fingolimod in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

To evaluate the safety and efficacy of fingolimod 0.5mg vs. placebo in MS patients in China

03

Conditions studied

  • Multiple Sclerosis (Relapsing Remitting)

Keywords

  • multiple sclerosis (MS)
  • relapsing remitting multiple sclerosis (RRMS)
  • fingolimod
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Patients must have relapsing remitting multiple sclerosis

Exclusion criteria

Exclusion Criteria:

Patients with:

  • History of chronic immune disease
  • Certain cancers
  • Uncontrolled diabetes
  • Certain eye disorders -Negative for varicella
  • zoster virus IgG antibodies
  • Certain hepatic conditions
  • Low white blood cell count
  • On certain medications or heart medications
  • Certain heart conditions or certain lung conditions
  • Inability to undergo MRI scans -Diagnosis of Neuromyelitis optica.
  • Other protocol defined inclusion/exclusion criteria may apply
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    double blinded Fingolimod 6 mos + open label fingolimod 6 mos

    Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily

    Drug: fingolimod

  • Placebo comparator
    Placebo 6 mos + open label fingolimod 6 mos

    Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily

    Drug: Placebo (6mos) + open label fingolimod (6 mos)

Interventions

  • Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily

  • DrugPlacebo (6mos) + open label fingolimod (6 mos)

    Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily

06

What researchers measure

Primary outcomes

  1. number of new/newly enlarged T2 MRI lesions over 6 months

    Cumulative number of new/newly enlarged T2 lesions over 6 months

    Time frame: 6 months

Secondary outcomes

  1. annualized relapse rate (ARR)

    The annualized relapse rate (ARR) is identified as the average number of confirmed relapses per year (the total number of confirmed relapses divided by the total days in the study multiplied by 365.25). The number of relapses will include all the confirmed relapses during the study. The time spent in the study will correspond to the observation period for all the relapses from first dose on the study drug to end of study.

    Time frame: 6 months

  2. number of Gd-enhancing T1 lesions

    Time frame: 6 months

  3. Safety and tolerability of fingolimod 0.5 mg compared to placebo

    Based on frequency of adverse events (the number and percentage of patients having any AE by primary system organ class and preferred term) and on the incidence of clinically notable abnormalities

    Time frame: 12 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of May 2017 and a completion of May 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2013
First posted
Sep 12, 2013
Start
Jun 2014
Primary completionEst.
May 2017
CompletionEst.
May 2017
Last update
Apr 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01941004
Responsible party
Sponsor
First posted
Sep 12, 2013
Start date
Jun 2014
Primary completion
May 2017 (estimated)
Completion
May 2017 (estimated)
Last update
Apr 21, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion